Organovo and Its Customers Present Data Supporting 3D Bioprinted Liver and Kidney Tissues for Drug Toxicity Testing
“We’re pleased by the strong early feedback on our newest product, the ExVive Human Kidney Tissue, and the ongoing uptake and validation of ExVive Human Liver Tissue by our customers and partners,” said Dr.
"Our powerful and versatile technology platform delivers 3D bioprinted tissues that provide an accurate, predictive and reproducible model of human liver and kidney biology for preclinical toxicity testing,” said
The presented data supports the use of the ExVive Human Liver and Kidney Tissue Models in:
- Differentiating high-risk compounds from low-risk to evaluate the multiple pathways and mechanisms of DILI.
- Identifying the metabolite-driven tox mechanisms of compounds such as acetaminophen in a concentration- and dose-dependent manner, thereby modeling tissue-level clinical outcomes in vitro.
- Characterizing the role of Kupffer cells (KCs) in modulating the outcome of drug-induced liver fibrosis.
- Demonstrating sustained metabolic capacity over time in terms of metabolic enzyme expression, metabolite formation, and gene expression levels to assess slow developing DILI toxicities.
- Illustrating the multiple mechanisms of nephrotoxicity to evaluate the progression and subsequent recovery of tissue-level injury.
- Assessing the expression, polarized localization and function of renal transporters involved in drug-induced renal toxicity.
In addition, the Colgate-Palmolive Award for Student Research Training in Alternative Methods, which is supported by
The presentations are as follows:
Scientific Symposium | ||
Title: | Utilization of Bioprinted Human Liver Tissues for Toxicology Applications and Disease Modeling | |
Date: | March 13, 11:10 a.m. - 11:45 a.m. ET, Ballroom II | |
Presenter: | Rhiannon Hardwick, Ph.D., Organovo | |
Exhibitor-Hosted Sessions | ||
Title: | Simplifying the Complex: Using 3D Bioprinted Kidney Tissue to Unravel the Intricate Mechanisms of Drug-Induced Nephrotoxicity | |
Date: | March 13, 4:30 p.m. - 5:30 p.m. ET, Room 340 | |
Presenter: | Deborah G. Nguyen, Ph.D., Organovo | |
Title: | The Advantages of ExViveTM 3D Bioprinted Liver Tissue in Elucidating Clinically Relevant Mechanisms of Drug-Induced Hepatoxicity | |
Date: | March 15, 1:30 p.m. - 2:30 p.m. ET, Room 340 | |
Presenters: | Sharon Collins Presnell, Ph.D., Organovo | |
Leah M. Norona, Doctoral Candidate, The University of North Carolina at Chapel Hill | ||
Poster Presentations | ||
Title: | Utilization of the ExVive Human Liver Tissue Model to Assess Drug-Induced Liver Injury Across a Diverse Set of Chemical Classes | |
Presenter: | Candace M. Crogan-Grundy, Ph.D., Organovo | |
Poster: | 1246: Poster Board - P406 | |
Title: | Utilization of the ExVive Human Kidney Tissue Model of Proximal Tubule to Assess Nephrotoxicity Across a Diverse Set of Chemical Classes | |
Presenter: | J. William Higgins, Organovo | |
Poster: | 1804: Poster Board – P344 | |
Title: | Mechanistic Study of Acetaminophen-Induced Liver Injury Using a 3D Bioprinted Human Liver Tissue Model | |
Presenter: | Masato Ohbuchi, Ph.D., Astellas Pharma Inc. | |
Poster: | 1653: Poster Board – P105 | |
Title: | 3D Bioprinted Human Liver: Metabolic and Transcriptional Characterization | |
Presenter: | Andreas Baudy, Ph.D., Merck & Co., Inc. | |
Poster: | 3274: Poster Board – P243 | |
Title: | Temporal Characterization of a 3D Bioprinted Model May Provide New Insight into Events Underlying Fibrotic Liver Injury | |
Presenter: | Leah M. Norona, Doctoral Candidate, The University of North Carolina at Chapel Hill | |
Poster: | 3373: Poster Board - P344 | |
Exhibit Booth: March 13-15, 9:15 a.m. - 4:30 p.m. ET, Booth 2057, CC Exhibit Hall | ||
About
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the Company’s ability to successfully complete studies and provide the technical information required to support market acceptance of its products, services and technology, on a timely basis or at all; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, including its use of third party distributors; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships; the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all; and the Company’s ability to meet its fiscal year 2017 outlook and/or its long-range outlook. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2016 and its Quarterly Report on Form 10-Q filed with the
Investor Contact: Steve KunszaboOrganovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Press Contact:Jessica Yingling , Ph.D.Little Dog Communications +1 (858) 480-2411 jessica@litldog.com